TNF-alpha inhibitors in organ transplant recipients: a retrospective cohort study

Abstract Tumor necrosis factor-alpha inhibitors (TNFi) can be an effective treatment for organ transplant recipients (OTR) with various diseases but can increase the risk of infection and drug interactions.1 There is also a potential for acute graft rejection while on TNFi with an unclear causal relationship. Two patients experienced acute graft rejection out of sixteen in a retrospective study of kidney transplant patients on TNFi, but the rejections were deemed unlikely to be related to biologic use.4 The purpose of this larger, multicenter study was to evaluate the safety of TNFi use in OTR by assessing rates of complications in patients treated with TNFi post-transplant.